Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease

References

• Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57–87.
   PubMed Web of Science ®Google Scholar
• Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44:S72–84.
   PubMed Web of Science ®Google Scholar
• Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53:S26–S38.
   PubMed Web of Science ®Google Scholar
• Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007;208:1–25.
   PubMed Web of Science ®Google Scholar
• Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4 + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009;119: 182–192.
   PubMed Web of Science ®Google Scholar
• Pilleri M, Antonini A. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. Expert Opin Drug Saf 2015;14:281–294.
   PubMed Web of Science ®Google Scholar
• Broadstock M, Ballard C, Corbett A. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin Pharmacother 2014;15:1797–1810.
   PubMed Web of Science ®Google Scholar
• Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004;75:637–639.
   PubMed Web of Science ®Google Scholar
• Caroline MT, Melanie B, Ray ED. Parkinson Disease: A Global View. XIX,2. Parkinson Report. http://www.parkinson.org/NationalParkinsonFoundation/files/da/da332eb3-ecaa-464f-adfb-b61a80851160.pdf>. Last Accessed 2008.
   Google Scholar
• Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998;13:221–227.
   PubMed Web of Science ®Google Scholar
• Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007;150: 963–976.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009;27: 119–145.
   PubMed Web of Science ®Google Scholar
• Gatto EM, Riobo NA, Carreras MC, Chernavsky A, Rubio A, Satz ML, Poderoso JJ. Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease. Nitric Oxide 2000;4:534–539.
   PubMed Web of Science ®Google Scholar
• Duncan AJ, Heales SJ. Nitric oxide and neurological disorders. Mol Aspects Med 2005;26:67–96.
   PubMedGoogle Scholar
• Zhang L, Dawson VL, Dawson TM. Role of nitric oxide in Parkinson's disease. Pharmacol Ther 2006;109:33–41.
   PubMed Web of Science ®Google Scholar
• Singh S, Dikshit M. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain Res Rev 2007; 54:233–250.
   PubMed Web of Science ®Google Scholar
• Li X, Ye X, Sun X, Liang Q, Tao L, Kang X, Chen J. Salidroside protects against MPP(+)-induced apoptosis in PC12 cells by inhibiting the NO pathway. Brain Res 2011;1382:9–18.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005;11 Suppl 1:S9–S15.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012;18 Suppl 1:S210–212.
   PubMedGoogle Scholar
• Rezai-Zadeh K, Gate D, Town T. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol 2009;4:462–475.
   PubMed Web of Science ®Google Scholar
• Mohanakumar KP, Hanbauer I, Chiueh CC. Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity. J Chem Neuroanat 1998;14:195–205.
   PubMed Web of Science ®Google Scholar
• Mohanakumar KP, Steinbusch HW. Hydroxyl radicals and nitric oxide in neurotoxicity and neuroprotection. J Chem Neuroanat 1998;14:125–127.
   PubMed Web of Science ®Google Scholar
• Rauhala P, Khaldi A, Mohanakumar KP, Chiueh CC. Apparent role of hydroxyl radicals in oxidative brain injury induced by sodium nitroprusside. Free Radic Biol Med 1998;24: 1065–1073.
   PubMed Web of Science ®Google Scholar
• Rauhala P, Mohanakumar KP, Sziraki I, Lin AM, Chiueh CC. S-nitrosothiols and nitric oxide, but not sodium nitroprusside, protect nigrostriatal dopamine neurons against iron-induced oxidative stress in vivo. Synapse 1996;23:58–60.
   PubMed Web of Science ®Google Scholar
• Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12:905–912.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Saravanan KS, Thomas B, Sindhu KM, Mohanakumar KP. Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats. Neurochem Res 2008;33:985–995.
   PubMed Web of Science ®Google Scholar
• Thomas T, Timmer M, Cesnulevicius K, Hitti E, Kotlyarov A, Gaestel M. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation—relevance in a mouse model of Parkinson's disease. J Neurochem 2008;105:2039–2052.
   PubMed Web of Science ®Google Scholar
• Madathil KS, Karuppagounder SS, Haobam R, Varghese M, Rajamma U, Mohanakumar KP. Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats. Neurochem Int 2013;62:674–683.
   PubMed Web of Science ®Google Scholar
• Laranjinha J, Santos RM, Lourenco CF, Ledo A, Barbosa RM. Nitric oxide signaling in the brain: translation of dynamics into respiration control and neurovascular coupling. Ann N Y Acad Sci 2012;1259:10–18.
   PubMed Web of Science ®Google Scholar
• Underbakke ES, Iavarone AT, Chalmers MJ, Pascal BD, Novick S, Griffin PR, Marletta MA. Nitric oxide-induced conformational changes in soluble guanylate cyclase. Structure 2014;22:602–611.
   PubMed Web of Science ®Google Scholar
• Ju TC, Chen SD, Liu CC, Yang DI. Protective effects of S-nitrosoglutathione against amyloid beta-peptide neurotoxicity. Free Radic Biol Med 2005;38:938–949.
   PubMed Web of Science ®Google Scholar
• Iyer AK, Rojanasakul Y, Azad N. Nitrosothiol signaling and protein nitrosation in cell death. Nitric Oxide 2014;42C:9–18.
   Google Scholar
• Halliwell B, Gutteridge J. Free radicals in biology and medicine. Oxford: Clarendon Press; 1999.
   Google Scholar
• Girard P, Potier P. NO, thiols and disulfides. FEBS Lett 1993; 320:7–8.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Wang L, Wong CC, Scott FL, Eckelman BP, Han X, et al. Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol Cell 2010;39:184–195.
   PubMed Web of Science ®Google Scholar
• Ayton S, Lei P, Hare DJ, Duce JA, George JL, Adlard PA, et al. Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J Neurosci 2015;35:3591–3597.
   PubMed Web of Science ®Google Scholar
• Han JY, Kang MJ, Kim KH, Han PL, Kim HS, Ha JY, Son JH. Nitric oxide induction of parkin translocation in PTEN-induced putative kinase 1 (PINK1) deficiency: Functional role of neuronal nitric oxide synthase during mitophagy. J Biol Chem 2015;290:10325–10335.
   PubMed Web of Science ®Google Scholar
• Yin L, Xie Y, Yin S, Lv X, Zhang J, Gu Z, et al. The S-nitrosylation status of pcna localized in cytosol impacts the apoptotic pathway in a Parkinson's disease paradigm. PLoS One 2015;10:e0117546.
   Google Scholar
• Bortolanza M, Cavalcanti-Kiwiatkoski R, Padovan-Neto FE, da-Silva CA, Mitkovski M, Raisman-Vozari R, Del-Bel E. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. Neurobiol Dis 2014;73C: 377–387.
   PubMedGoogle Scholar
• Choi MS, Nakamura T, Cho SJ, Han X, Holland EA, Qu J, et al. Transnitrosylation from DJ-1 to PTEN attenuates neuronal cell death in parkinson's disease models. J Neurosci 2014;34:15123–15131.
   PubMed Web of Science ®Google Scholar
• Sunico CR, Nakamura T, Rockenstein E, Mante M, Adame A, Chan SF, et al. S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease. Mol Neurodegener 2013;8:29.
   PubMedGoogle Scholar
• Nunes C, Barbosa RM, Almeida L, Laranjinha J. Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis. Mol Cell Neurosci 2011;48: 94–103.
   PubMed Web of Science ®Google Scholar
• Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008;28:7687–7698.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci U S A 2007;104:18742–18747.
   PubMed Web of Science ®Google Scholar
• Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006;441:513–517.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005;19:533–542.
   PubMed Web of Science ®Google Scholar
• Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004;304:1328–1331.
   PubMed Web of Science ®Google Scholar
• Bashkatova V, Alam M, Vanin A, Schmidt WJ. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp Neurol 2004;186:235–241.
   PubMed Web of Science ®Google Scholar
• Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22:1763–1771.
   PubMed Web of Science ®Google Scholar
• Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403–1409.
   PubMed Web of Science ®Google Scholar
• Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999;19:3440–3447.
   PubMed Web of Science ®Google Scholar
• Smith TS, Swerdlow RH, Parker WD Jr, Bennett JP Jr. Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 1994;5:2598–2600.
   PubMed Web of Science ®Google Scholar
• Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996;2:1017–1021.
   PubMed Web of Science ®Google Scholar
• Canals S, Casarejos MJ, de Bernardo S, Rodriguez-Martin E, Mena MA. Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. J Neurochem 2001; 79:1183–1195.
   PubMed Web of Science ®Google Scholar
• Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 1999;31: 577–596.
   PubMed Web of Science ®Google Scholar
• Peunova N, Enikolopov G. Nitric oxide triggers a switch to growth arrest during differentiation of neuronal cells. Nature 1995;375:68–73.
   PubMed Web of Science ®Google Scholar
• Kavya R, Saluja R, Singh S, Dikshit M. Nitric oxide synthase regulation and diversity: implications in Parkinson's disease. Nitric Oxide 2006;15:280–294.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhu DY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009;20:223–230.
   PubMed Web of Science ®Google Scholar
• Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A 2003;100:4843–4848.
   PubMed Web of Science ®Google Scholar
• Perez-Rodriguez R, Olivan AM, Roncero C, Moron-Oset J, Gonzalez MP, Oset-Gasque MJ. Glutamate triggers neurosecretion and apoptosis in bovine chromaffin cells through a mechanism involving NO production by neuronal NO synthase activation. Free Radic Biol Med 2014;69:390–402.
   PubMed Web of Science ®Google Scholar
• Li LL, Ginet V, Liu X, Vergun O, Tuittila M, Mathieu M, et al. The nNOS-p38MAPK pathway is mediated by NOS1AP during neuronal death. J Neurosci 2013;33:8185–8201.
   PubMed Web of Science ®Google Scholar
• Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med 2007;43:645–657.
   PubMed Web of Science ®Google Scholar
• Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A 2005;102: 1199–1204.
   PubMed Web of Science ®Google Scholar
• Di Matteo V, Pierucci M, Benigno A, Orban G, Crescimanno G, Esposito E, Di Giovanni G. Electrophysiological and neurochemical characterization of 7-nitroindazole and molsidomine acute and sub-chronic administration effects in the dopaminergic nigrostrial system in rats. J Neural Transm Suppl 2009;73:173–182.
   PubMedGoogle Scholar
• Sammut S, Dec A, Mitchell D, Linardakis J, Ortiguela M, West AR. Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism. Neuropsychopharmacology 2006;31:493–505.
   PubMed Web of Science ®Google Scholar
• Sammut S, Bray KE, West AR. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity. Psychopharmacology (Berl) 2007;191:793–803.
   PubMed Web of Science ®Google Scholar
• Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979–980.
   PubMed Web of Science ®Google Scholar
• Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464–467.
   PubMed Web of Science ®Google Scholar
• Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull 1984;20:548–553.
   PubMed Web of Science ®Google Scholar
• Donnan GA, Kaczmarczyk SJ, Solopotias T, Rowe P, Kalnins RM, Vajda FJ, Mendelsohn FA. The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals. Clin Exp Neurol 1986;22: 155–164.
   PubMedGoogle Scholar
• Mitra N, Mohanakumar KP, Ganguly DK. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B. J Neurochem 1994;62:1906–1912.
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Sieber BA, Manzino L, Sonsalla PK. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 1989;10:171–183.
   PubMedGoogle Scholar
• Haobam R, Sindhu KM, Chandra G, Mohanakumar KP. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res 2005;163:159–167.
   PubMed Web of Science ®Google Scholar
• Naskar A, Manivasagam T, Chakraborty J, Singh R, Thomas B, Dhanasekaran M, Mohanakumar KP. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res 2013;55:304–312.
   PubMed Web of Science ®Google Scholar
• Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 1999; 274:34621–34628.
   PubMed Web of Science ®Google Scholar
• Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72: 355–363.
   PubMed Web of Science ®Google Scholar
• Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000;74:2213–2216.
   PubMed Web of Science ®Google Scholar
• Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996;93:4565–4571.
   PubMed Web of Science ®Google Scholar
• Mackenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse 1997;26:301–316.
   PubMed Web of Science ®Google Scholar
• Thomas B, Muralikrishnan D, Mohanakumar KP. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res 2000;852:221–224.
   PubMed Web of Science ®Google Scholar
• Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24: 485–493.
   PubMedGoogle Scholar
• Borah A, Mohanakumar KP. L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients. Med Hypotheses 2012;79:271–273.
   PubMed Web of Science ®Google Scholar
• Borah A, Mohanakumar KP. L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochem Int 2010;56: 357–362.
   PubMed Web of Science ®Google Scholar
• Borah A, Mohanakumar KP. Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism. Brain Res 2010;1344: 192–199.
   PubMed Web of Science ®Google Scholar
• Senthilkumar KS, Saravanan KS, Chandra G, Sindhu KM, Jayakrishnan A, Mohanakumar KP. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. Behav Brain Res 2007;184: 11–18.
   PubMed Web of Science ®Google Scholar
• Sindhu KM, Banerjee R, Senthilkumar KS, Saravanan KS, Raju BC, Rao JM, Mohanakumar KP. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol Biochem Behav 2006;84:321–329.
   PubMed Web of Science ®Google Scholar
• Curtius HC, Wolfensberger M, Steinmann B, Redweik U, Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 1974;99:529–540.
   PubMed Web of Science ®Google Scholar
• Evans J, Cohen G. Catecholamine uptake inhibitors elevate 6-hydroxydopamine in brain after administration of 6-hydroxydopa. Eur J Pharmacol 1993;232:241–245.
   PubMed Web of Science ®Google Scholar
• Liao PC, Kuo YM, Chang YC, Lin C, Cherng CF, Yu L. Striatal formation of 6-hydroxydopamine in mice treated with pargyline, pyrogallol and methamphetamine. J Neural Transm 2003;110:487–494.
   PubMed Web of Science ®Google Scholar
• Borah A, Mohanakumar KP. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res 2009; 47:293–300.
   PubMed Web of Science ®Google Scholar
• Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 1993;18:1175–1177.
   PubMed Web of Science ®Google Scholar
• Maharaj H, Sukhdev Maharaj D, Scheepers M, Mokokong R, Daya S. l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 2005;1063:180–186.
   PubMed Web of Science ®Google Scholar
• Riobo NA, Schopfer FJ, Boveris AD, Cadenas E, Poderoso JJ. The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease. Free Radic Biol Med 2002; 32:115–121.
   PubMed Web of Science ®Google Scholar
• Tuncel N, Korkmaz OT, Tekin N, Sener E, Akyuz F, Inal M. Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. J Mol Neurosci 2012;46:51–57.
   PubMed Web of Science ®Google Scholar
• Barthwal MK, Srivastava N, Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep 2001;6:297–302.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114:1953–1975.
   PubMed Web of Science ®Google Scholar
• Mohanakumar KP, de Bartolomeis A, Wu RM, Yeh KJ, Sternberger LM, Peng SY, et al. Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation. Ann N Y Acad Sci 1994;738:392–399.
   PubMed Web of Science ®Google Scholar
• Sziraki I, Mohanakumar KP, Rauhala P, Kim HG, Yeh KJ, Chiueh CC. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience 1998;85: 1101–1111.
   PubMed Web of Science ®Google Scholar
• Schipper HM, Vininsky R, Brull R, Small L, Brawer JR. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp Neurol 1998;152: 188–196.
   PubMed Web of Science ®Google Scholar
• Pezzella A, d’Ischia M, Napolitano A, Misuraca G, Prota G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J Med Chem 1997;40:2211–2216.
   PubMed Web of Science ®Google Scholar
• Mohanakumar KP, Thomas B, Sharma SM, Muralikrishnan D, Chowdhury R, Chiueh CC. Nitric oxide: an antioxidant and neuroprotector. Ann N Y Acad Sci 2002;962:389–401.
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301–1306.
   PubMed Web of Science ®Google Scholar
• Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002;136:317–324.
   PubMed Web of Science ®Google Scholar
• Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, Chesselet MF. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 2004; 187:418–429.
   PubMed Web of Science ®Google Scholar
• Sindhu KM, Saravanan KS, Mohanakumar KP. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 2005;1051:25–34.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Haobam R, Nair R, Mohanakumar KP. Engraftment of mouse embryonic stem cells differentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats. PLoS One 2013;8:e72501.
   PubMedGoogle Scholar
• Saravanan KS, Sindhu KM, Mohanakumar KP. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 2005;1049:147–155.
   PubMed Web of Science ®Google Scholar
• Saravanan KS, Sindhu KM, Mohanakumar KP. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res 2007;42:247–253.
   PubMed Web of Science ®Google Scholar
• Chou AP, Li S, Fitzmaurice AG, Bronstein JM. Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology 2010;31:367–372.
   PubMed Web of Science ®Google Scholar
• Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int 2006;49:28–40.
   PubMed Web of Science ®Google Scholar
• Madathil SK, Karuppagounder SS, Mohanakumar KP. Sodium salicylate protects against rotenone-induced parkinsonism in rats. Synapse 2013;67:502–514.
   PubMed Web of Science ®Google Scholar
• Karuppagounder SS, Madathil KS, Pandey M, Haobam R, Rajamma U, Mohanakumar KP. Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats. Neuroscience 2013;236:136–148.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38:1285–1291.
   PubMed Web of Science ®Google Scholar
• Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46: 598–605.
   PubMed Web of Science ®Google Scholar
• Castano A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998;70:1584–1592.
   PubMed Web of Science ®Google Scholar
• Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000;20:6309–6316.
   PubMed Web of Science ®Google Scholar
• Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000;295:125–132.
   PubMed Web of Science ®Google Scholar
• Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002;110:49–58.
   PubMed Web of Science ®Google Scholar
• Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002;81:1285–1297.
   PubMed Web of Science ®Google Scholar
• Gao HM, Liu B, Zhang W, Hong JS. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J 2003;17:1957–1959.
   PubMed Web of Science ®Google Scholar
• Fahrig T, Gerlach I, Horvath E. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury. Mol Pharmacol 2005;67:1544–1555.
   PubMed Web of Science ®Google Scholar
• Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, et al. 3-Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 2005;19:395–397.
   PubMedGoogle Scholar
• Zhang D, Hu X, Wei SJ, Liu J, Gao H, Qian L, et al. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. J Neuroinflammation 2008;5:21.
   PubMed Web of Science ®Google Scholar
• Cho Y, Son HJ, Kim EM, Choi JH, Kim ST, Ji IJ, et al. Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox Res 2009;16:361–371.
   PubMed Web of Science ®Google Scholar
• Hancock DB, Martin ER, Vance JM, Scott WK. Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics 2008;9:249–262.
   PubMed Web of Science ®Google Scholar
• Rife T, Rasoul B, Pullen N, Mitchell D, Grathwol K, Kurth J. The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson's disease. J Neurosci Res 2009;87:2319–2325.
   PubMed Web of Science ®Google Scholar
• Lo HS, Hogan EL, Soong BW. 5’-flanking region polymorphism of the neuronal nitric oxide synthase gene with Parkinson’s disease in Taiwan. J Neurol Sci 2002;194:11–13.
   PubMed Web of Science ®Google Scholar
• Bockelmann R, Wolf G, Ransmayr G, Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J Neural Transm Park Dis Dement Sect 1994;7:115–121.
   PubMedGoogle Scholar
• Eve DJ, Nisbet AP, Kingsbury AE, Hewson EL, Daniel SE, Lees AJ, et al. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res Mol Brain Res 1998;63:62–71.
   PubMedGoogle Scholar
• Yin GN, Jeon H, Lee S, Lee HW, Cho JY, Suk K. Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res 2009;87:2578–2590.
   PubMed Web of Science ®Google Scholar